Modifying platelets at their birth: anti-thrombotic therapy without haemorrhage
Cardiovascular disease is a leading cause of death. The current approach to the prevention of arterial thrombosis in cardiovascular disease is dependent on the use of therapies which inhibit the activation of platelets. Predictably these are associated with an increased risk of haemorrhage which cau...
Main Authors: | Conor Feely, Nitika Kaushal, Pier Paolo D’Avino, John Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1343896/full |
Similar Items
-
Platelets and megakaryocytes /
by: Gibbins, Jonathan M., et al.
Published: (c200) -
Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia
by: Lamya Garabet, et al.
Published: (2019-02-01) -
Blood and Bone: The quarantine chronicles
by: Kirk A. Taylor, et al.
Published: (2020-07-01) -
Platelet <i>Versus</i> Megakaryocyte: Who Is the Real Bandleader of Thromboinflammation in Sepsis?
by: Cédric Garcia, et al.
Published: (2022-04-01) -
Small GTPases in megakaryocyte and platelet biology
by: Lucia Stefanini, et al.
Published: (2019-01-01)